로딩 중…
StockDiggingStockDigging

Bioventus Inc.

BVS· NASDAQ
$12.91+2.22%
2026-09-18

Financials

Valuation Metrics

Bioventus Inc.'s Market Cap is $875M. At end of 2025 it was $496M. Ranked #2548 of 3,121 in US market (top 82%), #1063 of 1,463 on NASDAQ (top 73%), #158 of 205 in Health Care Equipment & Services (top 77%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$875M
Revenue$582M
Net Income$54M
Total Assets$673M
Net Assets$228M
Employees950
Value
P/E16.06x
P/B3.83x
P/S1.50x
EV/EBITDA11.95x
FCF Yield10.78%
Profitability
ROE23.86%
ROA8.09%
Op. Margin10.63%
Revenue Growth3.14%
Financial Health
Debt Ratio173.42%
Total Debt$264M
FCF$94M
Cash$29M
Current Ratio1.69x
Net Debt/EBITDA2.52x
Performance
1Y Return79.31%
1M Return-12.06%
From 52W High-18.75%
1Y MDD-27.51%
Trading
Volume690,078 shares
Trading Value$9M
Per Share
EPS$0.80
BPS$3.37

Company Info

CEO Robert Claypoole
Employees 950
HQ Durham, US

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.